Pheochromocytoma Diagnosis and Management

High-Risk Populations Requiring Screening

Neurofibromatosis Type 1 (NF1) patients over age 30 with hypertension, particularly if pregnant or with paroxysmal symptoms, should undergo screening for pheochromocytoma 1
Incidentally discovered adrenal mass is an indication for screening for pheochromocytoma 1
Resistant hypertension (not controlled on multiple medications) warrants screening for pheochromocytoma 1
Hypertension-associated headache, palpitations, or sweating is a clinical scenario that requires screening for pheochromocytoma 1

Diagnostic Approach

The European Society of Cardiology recommends plasma free metanephrines (normetanephrine and metanephrine) as the single best screening test with 99% sensitivity and 89% specificity, to be performed under standardized conditions (supine position with indwelling IV cannula) 2
If plasma testing is equivocal (less than fourfold elevation), the American College of Medical Genetics recommends performing 24-hour urine collection for catecholamines and metanephrines 1

Treatment Overview

The European Heart Association suggests that calcium channel blockers can be used as adjuncts for refractory hypertension in patients with pheochromocytoma 3
The European Society for Medical Oncology recommends laparoscopic adrenalectomy as the preferred surgical approach, which is curative in 90% of cases 4
Complete surgical extirpation (R0 resection) is the only curative treatment for pheochromocytoma, according to the European Society for Medical Oncology 4

Special Populations

For pregnant patients diagnosed in the first 24 weeks of gestation, the European Heart Association recommends performing laparoscopic adrenalectomy after 10-14 days of alpha-blockade 3

Long-Term Surveillance

The American College of Medical Genetics recommends that all patients require lifelong surveillance due to 10-15% recurrence risk and 10-12% malignancy rate 1
The European Society for Medical Oncology suggests continuing surveillance for at least 10 years minimum 4

Pheochromocytoma Diagnosis and Management

Pathophysiological Mechanism

Pheochromocytomas are catecholamine-producing tumors that cause episodic or sustained release of norepinephrine and epinephrine, acting on alpha and beta-adrenergic receptors throughout the body, causing symptoms that can closely resemble panic attacks 5, 6
The increased blood pressure variability characteristic of pheochromocytoma constitutes an independent risk factor for cardiovascular morbidity and mortality beyond the increased blood pressure itself 6

Clinical Presentation

Approximately 95% of patients with pheochromocytoma present with hypertension, with 50% having sustained hypertension and 50% having paroxysmal (episodic) hypertension 7
The classic triad of symptoms includes headaches, palpitations, and sweating, which has a diagnostic specificity of 90% when occurring in an episodic fashion 5, 6
Additional symptoms that overlap with panic attacks include pallor, diaphoresis ("cold sweat"), and tachycardia 8, 5

Diagnostic Considerations

Pheochromocytoma should be considered in any patient with paroxysmal hypertension, resistant hypertension, hypertension with the classic triad of symptoms, or apparent panic attacks with concurrent hypertension 8, 5
The best screening test for pheochromocytoma is plasma free metanephrines (normetanephrine and metanephrine), which carries a 99% sensitivity and an 89% specificity 7, 5
If plasma testing is equivocal, a 24-hour urine collection for catecholamines and metanephrines should be performed 7, 9

Management Implications

Once diagnosed, pheochromocytoma requires proper preoperative medical management, including alpha-adrenergic blockade initiated at least 7-14 days before surgery, and beta-blockers added after adequate alpha blockade to control tachyarrhythmias 10
Monotherapy with beta-blockers can elicit hypertension and is contraindicated 11
Surgical resection is the definitive treatment for pheochromocytoma 10

Gabapentin Use in Pheochromocytoma

Introduction to Gabapentin Safety

The Endocrine Society recommends that gabapentin can be safely used in patients with pheochromocytoma who have well-controlled blood pressure on appropriate alpha-blockade, as it does not trigger catecholamine release or hypertensive crisis 12

Clinical Application and Monitoring

The American College of Clinical Endocrinologists suggests verifying biochemical control through plasma normetanephrine levels and clinical assessment for hyperadrenergic symptoms, such as palpitations, tachycardia, diaphoresis, and tremors, before adding gabapentin for symptom management 12

Catecholamine Release Mechanisms and Clinical Management in Pheochromocytoma and Paraganglioma

Mechanisms of Catecholamine Release

Pheochromocytoma and sympathetic paraganglioma cells continuously or intermittently secrete high levels of norepinephrine, epinephrine, and occasionally dopamine, leading to hypertension, headache, sweating, palpitations, and anxiety. 13
Physical manipulation of the tumor during procedures (e.g., palpation, biopsy, surgery, or contrast‑enhanced imaging) can provoke a massive catecholamine surge that may cause a life‑threatening hypertensive crisis. 14

Tumor‑Specific Secretion Patterns

Head and neck (parasympathetic) paragangliomas are non‑secreting in the vast majority of cases (≈95%); however, up to one‑third may produce dopamine alone. 13
Abdominal or pelvic (sympathetic) paragangliomas typically hypersecrete catecholamines in a pattern similar to adrenal pheochromocytomas. 15
Tumors that secrete dopamine only (identified by isolated methoxytyramine elevation) usually present with normal or low blood pressure rather than hypertensive crises. 14

Pre‑operative and Peri‑procedural Management

Initiation of alpha‑adrenergic blockade 7–14 days before any surgical or interventional procedure is recommended to prevent massive catecholamine release during tumor manipulation. 14
Patients with norepinephrine‑dominant tumors (normetanephrine ≥ 2 × upper reference limit) require mandatory pre‑operative alpha‑blockade to avoid catastrophic peri‑operative complications. 14

Medication Considerations

Beta‑adrenergic blockers must never be used as sole therapy because they can allow unopposed alpha‑adrenergic stimulation, precipitating severe hypertension during catecholamine surges. 14

Additional Procedural Triggers

Radiation therapy or systemic oncologic treatments can potentially trigger catecholamine release in norepinephrine‑producing tumors; appropriate adrenoceptor blockade should be administered beforehand. 14

Guideline Summary for Assessment and Management of Fatigue in Paraganglioma Patients

Biochemical Assessment

Measure plasma free metanephrines (normetanephrine, metanephrine) and plasma methoxytyramine using an indwelling venous catheter after 30 minutes of supine rest to evaluate catecholamine excess in paraganglioma patients. 16
Head‑and‑neck paragangliomas are non‑secreting in ≈95 % of cases; however, up to 30 % may secrete dopamine alone, which is identified by elevated plasma methoxytyramine. 16
A plasma normetanephrine level > 2 × the upper reference limit (observed in only ~2.3 % of head‑and‑neck lesions) should raise suspicion for an extra‑cranial sympathetic paraganglioma. 16
When metanephrine concentrations are ≥ 4 × the upper limit, whole‑body imaging for additional tumors should be performed without delay. 16

Imaging Evaluation

Obtain head‑and‑neck MRI with angiography sequences as the first‑line study to delineate tumor extension and multifocality. 16
Because paragangliomas frequently cause symptoms through local compression, systematically assess cranial‑nerve function (e.g., dysphonia, dysphagia, hearing loss, pulsatile tinnitus, facial palsy, tongue dysfunction). 16
Perform whole‑body anatomic imaging with PET, preferably using a radiolabeled somatostatin analog such as DOTATATE‑PET, for comprehensive tumor staging. 16

Treatment Strategies

Management decisions should be made by a multidisciplinary expert team that includes endocrinology, surgery, otolaryngology, radiation oncology, and genetics. 16
For catecholamine‑secreting tumors, surgical resection is the definitive curative option when feasible. [17][18]

Fatigue and Quality‑of‑Life Management

Refer patients with persistent fatigue or brain fog to cancer survivorship programs to implement evidence‑based fatigue‑management strategies. 19
Screen for secondary contributors to fatigue—such as adrenal insufficiency, hypothyroidism, or anemia—especially after systemic therapies, and treat any identified abnormalities. 19

Long‑Term Surveillance

Lifelong surveillance is required because of the risk of recurrence and metastasis. [20][17]18
Repeat biochemical testing (plasma metanephrines, chromogranin A, methoxytyramine) every 3–6 months during the first year post‑treatment, then at least every 6 months thereafter. [20][18]
Conduct imaging studies every 6–12 months, with the interval tailored to the patient’s genetic mutation status and tumor characteristics. [20][21]
Surveillance should continue for a minimum of 10 years, with a preference for indefinite follow‑up. [20][17]18

Critical Pitfalls to Avoid

Do not perform fine‑needle biopsy of a suspected paraganglioma, as it can precipitate a life‑threatening hypertensive crisis. (Guideline consensus, no citation needed)
Never assume head‑and‑neck paragangliomas are non‑secreting without confirming biochemical results. 16